Skip to main content
PELL BIO-MED TECHNOLOGY CO., LTD. logo

PELL BIO-MED TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 6949 ISIN · TW0006949001 TW Professional, scientific and technical activities
Open in API
Filings indexed 9 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country TW Taiwan
Listing TW 6949

About PELL BIO-MED TECHNOLOGY CO., LTD.

https://www.pellbmt.com

Pell Biologics & Medical Technology Co., Ltd. specializes in the research, development, and clinical application of advanced cell and gene therapies. The company’s core expertise lies in Chimeric Antigen Receptor T-cell (CAR-T) therapy, adoptive T-cell therapy, and stem cell-based regenerative medicine. Its primary R&D pipeline includes CD19 CAR-T treatments for B-cell lymphoma, alongside Cytokine-Induced Killer (CIK) and Dendritic Cell-Cytokine Induced Killer (DC-CIK) immunotherapies. In the field of regenerative medicine, the company develops adipose-derived stem cell (ADSC) applications for degenerative arthritis and tissue repair. Operating within GTP and GMP-compliant facilities, the company focuses on critical technologies for cell isolation, activation, and expansion to deliver personalized precision medicine and high-quality cellular products.

Recent filings

Filing Released Lang Actions
115年05月僑外投資持股
Regulatory Filings
2026-05-04 Chinese
公告本公司115年度第一季合併財務報告董事會召開日期
Report Publication Announcement Classification · 78% confidence The document is a short announcement disclosing the date of the board meeting to consider and approve the company’s 115 (2026) Q1 consolidated financial report. It does not contain the actual report data but merely schedules the report review. According to the classification rules, this is an announcement regarding the timing/publication of a company report, fitting the Report Publication Announcement category (RPA).
2026-04-27 Chinese
公司接獲獨立數據監測委員會(IDMC)通知，PL001 (CD19嵌合抗原受體T細胞製劑)之療效通過第二期臨床 試驗期中分析，達統計上顯著意義
Regulatory Filings Classification · 78% confidence The document is a company disclosure on a securities exchange information platform (公開資訊觀測站) reporting a mid‐trial Phase II clinical result notification from an independent data monitoring committee. It is a material event/corporate announcement rather than a full financial report, earnings release, management change, or other defined category. It does not attach a separate report but serves as a regulatory announcement of significant R&D progress. This fits the fallback category “Regulatory Filings” (RNS).
2026-04-23 Chinese
係因本公司有價證券於集中交易市場達公布注意交易資訊 標準，故公布相關財務業務等重大訊息，以利投資人區別瞭解
Earnings Release Classification · 75% confidence The document is a mandatory disclosure on Taiwan’s Market Observation Post System (MOPS) providing key summary financial figures (monthly revenue, quarterly and annual cumulative data, profits, EPS) following a notice by the Taiwan Stock Exchange. It is not a full interim report but an initial, high‐level announcement of periodic financial results (monthly and quarterly highlights). This matches the definition of an Earnings Release (ER) rather than a full Interim Report or regulatory notice fallback. Q4 2025
2026-04-15 Chinese
115年3月背書保證與資金貸與
Regulatory Filings Classification · 85% confidence The document is a Taiwanese regulatory disclosure from the Public Information Observatory showing monthly funding lendings and endorsement/guarantee balances between the listed parent company and its subsidiaries. It is not a full financial report, earnings release, management discussion, or any specialized category. It serves as a general compliance filing. Therefore, it falls under the fallback category of Regulatory Filings (RNS).
2026-04-08 Chinese
115年3月營業收入
Regulatory Filings Classification · 75% confidence The document is a summary table of monthly and cumulative operating revenue (營業收入淨額) published on the Taiwan MOPS (“公開資訊觀測站”). It provides statutory monthly revenue figures, year-on-year changes, and explanatory footnotes on IFRS and reporting policies. This is not a full annual or interim financial report, not an earnings release with narrative or guidance, nor a notice of a report publication – it is the actual regulatory disclosure of monthly revenue data. There is no specific global category for “monthly revenue summary,” so it falls into the general regulatory filings (fallback) category.
2026-04-08 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.